Priyadarshini Tamilselvan

Extended adjuvant temozolomide improves survival in glioblastoma: An 8-year experience from a South Indian regional cancer centre

Background: Glioblastoma (GBM) remains the most aggressive primary brain tumour with a dismal prognosis despite multimodal therapy. The optimal duration of adjuvant temozolomide (TMZ) remains debated. Methods: A retrospective analysis was conducted on 110 histologically confirmed...